Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Prior authorization for biologic disease-modifying antirheumatic drugs: a description of US Medicaid programs.

Fischer MA, Polinski JM, Servi AD, Agnew-Blais J, Kaci L, Solomon DH.

Arthritis Rheum. 2008 Nov 15;59(11):1611-7. doi: 10.1002/art.24191.

2.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

3.

Biologics for rheumatoid arthritis: an overview of Cochrane reviews.

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007848. doi: 10.1002/14651858.CD007848.pub2. Review.

PMID:
19821440
4.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

5.

[Effectiveness of TNF antagonists in routine clinical practice and costs].

Prokes M.

Vnitr Lek. 2009 Jan;55(1):45-53. Review. Czech.

PMID:
19227955
6.

Cost effectiveness of biologic therapies for plaque psoriasis.

Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR.

Am J Clin Dermatol. 2013 Aug;14(4):315-26. doi: 10.1007/s40257-013-0030-z. Review.

PMID:
23696234
7.

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.

Jobanputra P, Barton P, Bryan S, Burls A.

Health Technol Assess. 2002;6(21):1-110. Review. No abstract available.

8.

Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.

Eng G, Stoltenberg MB, Szkudlarek M, Bouchelouche PN, Christensen R, Bliddal H, Marie Bartels E.

Semin Arthritis Rheum. 2013 Oct;43(2):144-51. doi: 10.1016/j.semarthrit.2013.01.007. Epub 2013 Jul 6. Review.

PMID:
23838092
9.

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.

Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A.

BMC Musculoskelet Disord. 2008 Apr 17;9:52. doi: 10.1186/1471-2474-9-52. Review.

10.

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.

Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T.

Scand J Rheumatol. 2007 Nov-Dec;36(6):411-7. Review.

PMID:
18092260
11.

[Approved indications and other possible utilizations of anti-TNFα biologic drugs].

Grassi W, Montecucco C.

Reumatismo. 2005;57(4 Suppl):30-3. Review. Italian.

12.

[New drugs and treatment strategies for rheumatoid arthritis].

Fantini F.

Recenti Prog Med. 2003 Sep;94(9):361-79. Review. Italian.

PMID:
12942798
13.

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases.

Kalden JR.

Arthritis Res. 2002;4 Suppl 2:S34-40. Epub 2002 May 24. Review.

14.
15.

Disease-modifying anti-rheumatic drug use in pregnant women with rheumatic diseases: a systematic review of the risk of congenital malformations.

Baldwin C, Avina-Zubieta A, Rai SK, Carruthers E, De Vera MA.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):172-83. Epub 2016 Mar 3. Review.

PMID:
26940667
16.

Need for circumspection in prescribing tumor necrosis factor inhibitors and other biologic response modifiers.

Matteson EL.

Arthritis Rheum. 2002 Feb;47(1):1-4. Review. No abstract available.

PMID:
11932870

Supplemental Content

Support Center